Characterization of Anti-FGFR3 Antibodies

Centre Hospitalier Universitaire de Saint Etienne251 enrolled

Overview

Sensory neuronopathies affect sensory neuron in the posterior spinal ganglion. They are responsible for pain, balance disorder (ataxia) and the use of hands. They depend on multiple etiologies. In a retrospective study, the investigators showed that the anti-FGFR3 antibody is a diagnostic marker of a subset of sensory neuronopathies. The investigators believe that other antibodies can be discovered in patients who remain seronegative changing. However, the study is retrospective and only a small number of patients could be identified. Several points therefore need to be clarified or confirmed in a second prospective study.

In and out patients evaluated for a sensory neuropathy meeting the inclusion and non-inclusion criteria will be proposed to enter the study At inclusion the SSN diagnostic score is calculated and a blood sample is tested for anti-FGFR3 antibody. Follow up: Patients positive for anti-FGFR3 antibodies will be followed and evaluated clinically and electrophysiologically at 1, 6 and 12 months. A blood sample is taken at 6 and 12 months. A subgroup of patients negative for anti-FGFR3 antibodies will be randomly selected for evaluation at 1, 6 and 12 months.

Study Type

OBSERVATIONAL

Enrollment

251

Conditions

Sensory Peripheral Neuropathy

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A :Patients Male or female patient aged 18 years or more Patients with a clinically pure sensory peripheral neuropathy including : * idiopathic or dysimmune sensory neuronopathies * idiopathic or dysimmune distal axonal sensory neuropathy * sensory chronic inflammatory demyelinating polyradiculoneuropathy * idiopathic or dysimmune small fiber neuropathies * idiopathic or dysimmune trigeminal nerve neuropathy * positive to antibodies anti-FGFR3 B :Controls Male or female patient aged 18 years or more Patients with a clinically pure sensory peripheral neuropathy including : * idiopathic or dysimmune sensory neuronopathies * idiopathic or dysimmune distal axonal sensory neuropathy * sensory chronic inflammatory demyelinating polyradiculoneuropathy * idiopathic or dysimmune small fiber neuropathies * idiopathic or dysimmune trigeminal nerve neuropathy * negative to antibodies anti-FGFR3 Exclusion Criteria: * -Motor or sensory-motor neuropathies * Genetic, toxic, paraneoplasic neuropathies * Diabetic Neuropathy. * Neuropathy with Anti-MAG or anti-ganglioside IgM. * Pregnant or breastfeeding woman

Locations (17)

CHU Bordeaux

Bordeaux, France

CHU Clermont-Ferrand

Clermont-Ferrand, France

Chu Creteil

Créteil, France

CHU de Grenoble

Grenoble, France

CHU de Limoges

Limoges, France

Hospices Civils de Lyon

Lyon, France

AP-HM

Marseille, France

CHRU de Nantes

Nantes, France

CHU de NICE

Nice, France

Hôpital BICETRE

Paris, France

...and 7 more locations

Outcomes

Primary Outcomes

Evolution of clinical and electrophysiological pattern of the neuropathy for patients with anti-FGFR3 antibodies (composite measure),

Score to the Overall Disability Scale Score (ODSS), the Rankin Score, the International PrognosticScore (ISS).

Time frame: 6 months

Secondary Outcomes

Evolution of clinical and electrophysiological pattern of the neuropathy for patients with anti-FGFR3 antibodies (composite measure),

Score to the Overall Disability Scale Score (ODSS), the Rankin Score, the International PrognosticScore (ISS).

Time frame: 12 months

Description for patients with anti-FGFR3 antibodies of the immune context

Levels of Antibodies anti-FGFR3

Time frame: 6 months

Description for patients with anti-FGFR3 antibodies of the immune context

Levels of Antibodies anti-FGFR3

Time frame: 12 months

Patient evolution during one year for patients with anti-FGFR3 antibodies to a control group of sensory neuropathy without antibodies

Levels of Antibodies anti-FGFR3

Time frame: 12 months